CUE

Cue Biopharma Inc

• Seeking Alpha·09/21 21:14

  Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

• TipRanks·09/21 20:30

  B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff

• Seeking Alpha·09/21 15:20

  Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset

• TipRanks·09/21 12:29

  Cue Biopharma reports positive Phase 2 CUE-221 data

• Seeking Alpha·09/21 11:00

  At a glance: stocks gapping up premarket

• Dow Jones·09/21 10:59

  Cue Biopharma Shares Jump With Positive Results in Chronic Spontaneous Urticaria Trial

• NASDAQ·09/20 18:37

  Cue Biopharma's CUE-221 Meets Phase 2 Goals In Chronic Hives Study; Stock Up

• TipRanks·09/20 14:15

  Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

• Seeking Alpha·09/18 15:28

  Cue Biopharma is a new Buy at B. Riley on valuation

• Dow Jones·09/18 10:49

  Cue Biopharma Price Target Announced at $83.00/Share by B. Riley Securities

• TipRanks·09/18 09:35

  Cue Biopharma initiated with a Buy at B. Riley

• NASDAQ·08/17 10:15

  Cue Biopharma Q2 Net Loss Widens; Expects Phase 2 Data For CUE-221 In CSU By End Of Q3 2026

• TipRanks·08/17 08:49

  Cue Biopharma registers to sell 1.5M shares of common stock for holders

• Seeking Alpha·08/17 07:30

  Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M

• Dow Jones·08/14 20:06

  *Cue Biopharma 2Q Rev $7.88M >CUE